WANBURY

Wanbury Share Price

₹224.54 +4.36 (1.98%)

20 Nov, 2024 13:04

SIP TrendupStart SIP in WANBURY

Start SIP

Performance

  • Low
  • ₹215
  • High
  • ₹228
  • 52 Week Low
  • ₹91
  • 52 Week High
  • ₹290
  • Open Price₹220
  • Previous Close₹220
  • Volume60,323

Investment Returns

  • Over 1 Month -10%
  • Over 3 Month + 14.65%
  • Over 6 Month + 35.8%
  • Over 1 Year + 146.61%
SIP Lightning

Smart Investing Starts Here Start SIP with Wanbury for Steady Growth!

Invest Now

Wanbury Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 13.9
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 736
  • P/B Ratio
  • 26.3
  • Average True Range
  • 13.2
  • EPS
  • 8.43
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.09
  • RSI
  • 41.52
  • MFI
  • 55.84

Wanbury Financials

Wanbury Technicals

EMA & SMA

Current Price
₹224.54
+ 4.36 (1.98%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹238.45
  • 50 Day
  • ₹237.12
  • 100 Day
  • ₹221.89
  • 200 Day
  • ₹191.89

Resistance and Support

222.35 Pivot Speed
  • R3 242.19
  • R2 234.85
  • R1 229.69
  • S1 217.19
  • S2 209.85
  • S3 204.69

What's your outlook on Wanbury?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Wanbury manufactures and markets pharmaceutical products, focusing on active pharmaceutical ingredients (APIs) and formulations. The company serves global markets with a range of therapeutic solutions in areas like anti-diabetics, pain management, and gastrointestinal treatments.

Wanbury has an operating revenue of Rs. 577.20 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 10% is healthy, ROE of 200% is exceptional. The company has a high debt to equity of 293%, which can be a reason to worry. The stock from a technical standpoint is trading below to its 50DMA and around 17% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 22% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 20 which is a POOR score indicating inconsistency in earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Wanbury Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-12 Quarterly Results
2024-05-16 Audited Results
2024-01-24 Quarterly Results
2023-10-20 Quarterly Results & Preferential issue Inter-alia, to consider and evaluate proposals for raising of funds by way of a preferential issue/allotment and private placement to promoters/promoter group of the Company.

Wanbury F&O

Wanbury Shareholding Pattern

39.77%
0%
1.02%
0%
40.66%
18.55%

About Wanbury

  • NSE Symbol
  • WANBURY
  • BSE Symbol
  • 524212
  • ISIN
  • INE107F01022

Similar Stocks to Wanbury

Wanbury FAQs

Wanbury share price is ₹224 As on 20 November, 2024 | 12:50

The Market Cap of Wanbury is ₹735.6 Cr As on 20 November, 2024 | 12:50

The P/E ratio of Wanbury is 13.9 As on 20 November, 2024 | 12:50

The PB ratio of Wanbury is 26.3 As on 20 November, 2024 | 12:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23